Author:
Yang Yi,Xu Yanan,Wang Jun,Zhai Xueqin,Jiang Haibing
Abstract
Abstract
Background
Inflammation is involved in the pathogenesis and progression of coronary artery diseases (CADs), including acute coronary syndrome. The neutrophil-to-lymphocyte ratio (NLR) has been identified as a novel marker of the pro-inflammatory state. We aimed to evaluate the predictive efficacy of the NLR for the prognosis of patients with new-onset ACS.
Methods
We retrospectively included consecutive patients with new-onset ACS treated with emergency coronary angiography. NLR was measured at baseline and analyzed by tertiles. The severity of coronary lesions was evaluated by the Gensini score. Correlations of NLR with the severity of CAD and the incidence of major adverse cardiovascular diseases (MACEs) during follow-up were determined.
Results
Overall, 737 patients were included. The NLR was positively correlated with the severity of coronary lesions as assessed by Gensini score (P < 0.05). During the follow-up period (mean, 43.49 ± 23.97 months), 65 MACEs occurred. No significant association was detected between baseline NLR and the risk of MACEs during follow-up by either Kaplan–Meier or Cox regression analysis. Multivariable logistic regression analysis showed that a higher NLR was independently associated with coronary lesion severity as measured by the Gensini score (1st tertile vs. 3rd tertile hazard ratio [HR]: 0.527, P < 0.001, and 2nd tertile vs. 3rd tertile HR: 0.474, P = 0.025).
Conclusions
The NLR may be associated with coronary disease severity at baseline but is not associated with adverse outcomes in patients with new-onset ACS.
Ethics Approval Number
2019XE0208
Publisher
Springer Science and Business Media LLC
Subject
Cardiology and Cardiovascular Medicine
Reference36 articles.
1. Ridker PM, Everett Brendan M, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119–31.
2. Goldfine Allison B, Shoelson Steven E. Therapeutic approaches targeting inflammation for diabetes and associated cardiovascular risk. J Clin Invest. 2017;127:83–93.
3. Choi D-H, Kobayashi Y, Nishi T, et al. Combination of mean platelet volume and neutrophil to lymphocyte ratio predicts long-term major adverse cardiovascular events after percutaneous coronary intervention. Angiology. 2019;70:345–51.
4. Everett Brendan M, Pradhan Aruna D, Solomon Daniel H, et al. Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. Am Heart J. 2013;166(199–207):e15.
5. Libby P, Ridker PM, Hansson GK. In-flammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 2009;54:2129–38.